Gilenya-induced Changes in Heart Rate May Predict Degree of Drop in Lymphocytes, Study Reports
NOVEMBER 26, 2018 Assessing changes in a person’s heart rate can help to predict the degree to which lymphocyte numbers…
OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEARS IN RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
October 10, 2018 People with relapsing MS (RMS) treated sooner with OCREVUS had earlier reduction in disease activity and less…
Stuart Schlossman
COULD BE the FIRST SECONDARY MS TREATMENT IF APPROVED — Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability progression in typical SPMS patients
Novartis is hoping for approvals for its new multiple sclerosis therapy siponimod in the US and Europe next year after…
Stuart Schlossman
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS
EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS…
Stuart Schlossman
New Drug Could Help Kids With MS
By Dennis Thompson HealthDay Reporter WEDNESDAY, Sept. 12, 2018 (HealthDay News) — Researchers say the first drug for children with multiple…
Stuart Schlossman
Trial of fingolimod vs interferon beta-1a in pediatric multiple sclerosis
New England Journal of Medicine — Chitnis T, et al. | September 14, 2018 In this phase 3 trial, researchers compared fingolimod with interferon…
Stuart Schlossman
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis
Sep 13, 2018 Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures…
Stuart Schlossman
B cells among factors leading to brain lesions in multiple sclerosis
Date: September 4, 2018 Source: University of Zurich Summary: A team of researchers has shown that in multiple sclerosis, it…
Stuart Schlossman
Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Abstract BACKGROUND: Fampridine leads to significant walking improvements in many persons with multiple sclerosis (PwMS). However, a relevant proportion of PwMS…
Stuart Schlossman
Ocrelizumab: A Review in Multiple Sclerosis
Syed YY. CNS Drugs. 2018. Authors Syed YY1. Author information 1 Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New…
Stuart Schlossman
